Evidence map›Paper›PMID 26739637›Full record

ArticleToxicology letters2016

Progenitor-derived hepatocyte-like (B-13/H) cells metabolise 1'-hydroxyestragole to a genotoxic species via a SULT2B1-dependent mechanism.

Philip M Probert, Jeremy M Palmer, Wasma Alhusainy, Aimen O Amer, Ivonne M C M Rietjens, Steven A White, David E Jones, Matthew C Wright

Open access · hybridAbstract read
In one paragraph

Article in Toxicology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Philip M ProbertInstitute Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Jeremy M PalmerInstitute Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Wasma AlhusainyDivision of Toxicology, Wageningen University, Tuinlaan 5, 6703HE Wageningen, The Netherlands.
Aimen O AmerInstitute Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Ivonne M C M RietjensDivision of Toxicology, Wageningen University, Tuinlaan 5, 6703HE Wageningen, The Netherlands.
Steven A WhiteInstitute Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom.
David E JonesInstitute Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Matthew C WrightInstitute Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom. Electronic address: M.C.Wright@ncl.ac.uk.
Newcastle University · GBWageningen University & Research · NL

Funding

National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/K500471/1
6 · The paper itself

Abstract

Rat B-13 progenitor cells are readily converted into functional hepatocyte-like B-13/H cells capable of phase I cytochrome P450-dependent activation of pro-carcinogens and induction of DNA damage. The aim of the present study was to investigate whether the cells are also capable of Phase II sulphotransferase (SULT)-dependent activation of a pro-carcinogen to an ultimate carcinogen. To this end we therefore examined the bioactivation of the model hepatic (hepato- and cholangio-) carcinogen estragole and its proximate SULT1A1-activated genotoxic metabolite 1'-hydroxyestragole. Exposing B-13 or B-13/H cells to estragole (at concentrations up to 1mM) resulted in the production of low levels of 1'-hydroxyestragole, but did not result in detectable DNA damage. Exposing B-13/H cells - but not B-13 cells - to 1'-hydroxyestragole resulted in a dose-dependent increase in DNA damage in comet assays, confirmed by detection of N(2)-(trans-isoestragol-3'-yl)-2'-deoxyguanosine adducts. Genotoxicity was inhibited by general SULT inhibitors, supporting a role for SULTS in the activation of 1-hydroxyestragole in B-13/H cells. However, B-13 and B-13/H cells did not express biologically significant levels of SULT1A1 as determined by qRT-PCR, Western blotting and its associated 7-hydroxycoumarin sulphation activity. B-13 and B-13/H cells expressed - relative to intact rat liver - high levels of SULT2B1 (primarily the b isoform) and SULT4A1 mRNAs and proteins. B-13 and B-13/H cells also expressed the 3'-phosphoadenosine 5'-phosphosulphate synthase 1 required for the generation of activated sulphate cofactor 3'-phosphoadenosine 5'-phosphosulphate. However, only B-13/H cells expressed functional SULT activities towards SULT2B1 substrates DHEA, pregnenolone and 4 methylumbelliferone. Since liver progenitor cells are bi-potential and also form cholangiocytes, we therefore hypothesised that B-13 cells express a cholangiocyte-like SULT profile. To test this hypothesis, the expression of SULTs was examined in liver by RT-PCR and immunohistochemistry. SULT2B1 - but not SULT1A1 - was determined to be expressed in both rat and human cholangiocytes. Since 1'-hydroxyestragole exposure readily produced DNA injury in B-13/H cells, these data suggest that cholangiocarcinomas generated in rats fed estragole may be dependent, in part, on SULT2B1 activation of the 1'-hydroxyestragole metabolite.

Indexed as

Allylbenzene DerivativesAnimalsAnisolesArylsulfotransferaseCarcinogensCell LineComet AssayDehydroepiandrosteroneDNA DamageGene Expression RegulationHepatocytesHumansHymecromoneLiverPregnenoloneRats1'-hydroxyestragoleAllylbenzene DerivativesAnisolesArylsulfotransferaseCarcinogensDehydroepiandrosteroneestragoleHymecromonePregnenoloneSulfotransferasesSULT1A1 protein, humanSULT2B1 protein, humanCometEstragoleGenotoxicityLiverSulfotransferase

Identifiers

PMID26739637
PMCPMC4729325
OpenAlexW2202266949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.